|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005290,
umls-concept:C0006142,
umls-concept:C0013089,
umls-concept:C0021017,
umls-concept:C0205179,
umls-concept:C0246415,
umls-concept:C0456387,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1516213,
umls-concept:C1522326,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
14
|
|
pubmed:dateCreated |
2008-7-16
|
|
pubmed:abstractText |
To evaluate the role of microtubule-associated variables as potential predictors of response and clinical outcome in patients with advanced breast cancer receiving single-agent docetaxel or doxorubicin chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:Bernard-MartyChantalC,
pubmed-author:BisseryMarie-ChristineMC,
pubmed-author:CardosoFatimaF,
pubmed-author:Di LeoAngeloA,
pubmed-author:DumontetCharlesC,
pubmed-author:DurbecqVirginieV,
pubmed-author:GalmariniCarlos MCM,
pubmed-author:GancbergDavidD,
pubmed-author:LarsimontDenisD,
pubmed-author:PaesmansMarianneM,
pubmed-author:PiccartMartine JMJ,
pubmed-author:TreilleuxIsabelleI
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4511-6
|
|
pubmed:meshHeading |
pubmed-meshheading:18628466-Antineoplastic Agents,
pubmed-meshheading:18628466-Breast Neoplasms,
pubmed-meshheading:18628466-Doxorubicin,
pubmed-meshheading:18628466-Drug Resistance, Neoplasm,
pubmed-meshheading:18628466-Female,
pubmed-meshheading:18628466-Humans,
pubmed-meshheading:18628466-Immunohistochemistry,
pubmed-meshheading:18628466-Middle Aged,
pubmed-meshheading:18628466-Protein Isoforms,
pubmed-meshheading:18628466-Taxoids,
pubmed-meshheading:18628466-Tubulin,
pubmed-meshheading:18628466-Tumor Markers, Biological
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
|
|
pubmed:affiliation |
Université Claude Bernard Lyon 1, France.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
